CELC241220P10000
- 0.45
- 0.000.00%
Celcuity Newsroom
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Celcuity Announced Overall Survival Data From Two Patient Cohorts Evaluated In A Phase 1B Trial With Gedatolisib, A PI3K/mTORC1/2 Inhibitor, In Combination With Palbociclib And Either Letrozole Or Fulvestrant, In Patients With HR+, HER2-advanced Or...
Wall Street Set to Open Flat Thursday; Initial Jobless Claims Higher Than Expected
Investors Await Jobless Claims Data as Markets Tread Water in Thursday's Premarket
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $27 to $42
Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Celcuity Down Over 12%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Stifel Nicolaus Remains a Buy on Celcuity (CELC)
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $27
Celcuity's Strong Financial Position and Promising Drug Pipeline Support Buy Rating Despite Trial Delays
Express News | Needham Reiterates Buy on Celcuity, Maintains $23 Price Target
Celcuity Analyst Ratings
Express News | Celcuity Inc : Leerink Partners Cuts Target Price to $28 From $29
Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript Summary
Promising Outlook for Celcuity's Gedatolisib Highlighted by Positive Phase III Trial Progress
Celcuity | 10-Q: Q3 2024 Earnings Report
Celcuity Reports Q3 EPS (70c), Consensus (70c)
Celcuity GAAP EPS of -$0.70 Misses by $0.05
Celcuity | 8-K: Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update